Form 4: Coya Therapeutics CFO Granted 140K Stock Options

Coya Therapeutics' Chief Financial Officer, David S. Snyder, was granted 140,041 stock options with an exercise price of $4.73, vesting over 36 months.

Summary

• David S. Snyder, Chief Financial Officer of Coya Therapeutics, Inc. (COYA), was granted 140,041 stock options.
• The options have an exercise price of $4.73 per share.
• The grant date for these options was January 22, 2026.
• The options will vest in monthly installments over 36 months, subject to continuous service.
• The options expire on January 22, 2036.
• Upon a change in control of Coya Therapeutics, the options will vest immediately and become exercisable under the company's 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (stock option grant) which is generally viewed as neutral to slightly positive as it aligns management incentives with shareholder interests, without indicating any immediate operational or financial performance changes.

Positives

• The grant of stock options aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing performance and value creation.
• The vesting schedule over 36 months encourages long-term commitment and retention of key management.
• The accelerated vesting upon a change in control provides an incentive for management to consider strategic transactions that could benefit shareholders.

Negatives

• The issuance of stock options represents potential future dilution for existing shareholders if the options are exercised.

Risks

• The value of the stock options is subject to the future market price of Coya Therapeutics' common stock, which can be volatile.
• If the stock price does not exceed the exercise price of $4.73, the options may expire worthless.
• The company's performance and stock price are subject to various industry-specific and general market risks.

Future Outlook

The stock options will vest in monthly installments over the next 36 months, subject to continuous service. This indicates a future incentive structure for the CFO. The options have a long-term expiration date of January 22, 2036, allowing for potential future exercise if the stock price appreciates.

Industry Context

Granting stock options to executive officers is a common practice in the biotechnology and pharmaceutical industries, as well as other growth-oriented sectors, to attract, retain, and incentivize key talent. This aligns management's financial interests with the long-term performance of the company and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a Chief Financial Officer is a standard component of executive compensation packages across publicly traded companies, particularly in the biotech sector.
• The 36-month vesting schedule is typical for long-term incentive plans, designed to encourage executive retention and sustained performance.
• The provision for accelerated vesting upon a change in control is also a common feature in equity incentive plans, aligning with best practices for executive retention during M&A activities.

Corporate Governance

Related Party Transactions

• The grant of 140,041 stock options to David S. Snyder, the Chief Financial Officer, constitutes a related party transaction as it involves compensation to an executive officer.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from aligned management incentives for long-term value creation.
• Employees: The grant to the CFO is part of the company's overall compensation strategy, potentially setting a precedent or standard for other executive incentives.
• Management: David S. Snyder receives a significant equity incentive, aligning his financial interests with the company's performance.

Next Steps

• Continued vesting of the 140,041 stock options over the next 36 months.
• Potential future exercise of vested options by David S. Snyder.

Key Dates

Keywords

Coya Therapeutics, COYA, Stock Options, Form 4, Insider Transaction, Executive Compensation, David S. Snyder, Chief Financial Officer, Equity Incentive Plan, Vesting